Newsfeeds - Spark Newswire

4 minute read

Neurodegenerative Disease, Cancer Stocks Among Top Biotech Gainers In 2021

Today, 10:46 PM

Biotech stocks underperformed the broader market in the first half of 2021, with the iShares Nasdaq Biotechnology ETF (NASDAQ: IBB) advancing about 8% year-to-date compared to the roughly 14% gain for the S&P 500 Index.

ANVS

4 minute read

Biotech Losers In 2021 That Could Bounce Big In The Second Half

By Shanthi Rexaline

Today, 10:46 PM

Biotech stocks are tricky investment bets that require careful analysis and scrutiny. A stock that has fallen off a cliff in reaction to a binary event can neither be written off entirely nor picked as a bargain buy. A lot of background research should go into the stock, company pipeline, cash runway, and other factors before an investment decision can be made.

ATHA

2 minute read

The Week Ahead In Biotech: Focus On Chemocentryx FDA Decision, Conference Presentations In A Light Week

By Shanthi Rexaline

Today, 10:46 PM

Biotech stocks advanced for a second week in running, with stocks reacting to pending releases for the second quarter and the first-half of the year.

ABOS

4 minute read

The Daily Biotech Pulse: Iterum’s Regulatory Setback, Decision Day For Provention Bio, Cidara & Outset Medical Announce CFO Departures

By Shanthi Rexaline

Today, 10:46 PM

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 1)

ALXN

5 minute read

Attention Biotech Investors: Mark Your Calendar For July PDUFA Dates

By Shanthi Rexaline

Today, 10:46 PM

June was a month of plenty and also turned out to be a fruitful one from the perspective of Food and Drug Administration approvals. Regulatory reviews mostly produced positive verdicts, and rejections or no-decisions were few and far between.

ALBO

1 minute read

IBB Vs. XBI: Which Biotech ETF Has A Better Chart?

By Mark Putrino

Today, 10:46 PM

The SPDR S&P Biotech ETF (NYSE: XBI) is trading below an important resistance level, but the iShares Nasdaq Biotechnology ETF (NASDAQ: IBB) has broken out.

IBB